©The Author(s) 2024.
World J Psychiatry. Jun 19, 2024; 14(6): 767-783
Published online Jun 19, 2024. doi: 10.5498/wjp.v14.i6.767
Published online Jun 19, 2024. doi: 10.5498/wjp.v14.i6.767
Table 1 Commonly used antipsychotic drugs and antidepressants, main mechanism of action and weight gain
| Antipsychotic drugs | Main mechanism of action[23-25] | Main mechanism of action[28,29] | Weight gain[8,26,27] | Weight gain[31,32] |
| Typical APs | ||||
| Chloropromazine | Blocks post-synaptic dopamine D2 receptors in the brain | +++ | ||
| Haloperidol | Blocks post-synaptic dopamine D2 receptors in the brain | + | ||
| Thiothixene | Blocks post-synaptic dopamine D1, D2, D3, D4 receptors in the brain | +++ | ||
| Fluphenazine | Blocks post-synaptic dopamine D1 and D2 receptors in the brain | + | ||
| Atypical APs | ||||
| Clozapine | Blocks dopamine D2 and 5HT serotonin receptors in the brain | +++ | ||
| Olanzapine | Blocks dopamine D1, D2, D3, D4 receptors, and serotonin 5HT2A, 5HT2C, 5HT3 and 5HT6, the alpha-1 adrenergic receptor | +++ | ||
| Quetiapine | Blocks dopamine D2 and serotonin 5HT2A receptors | +++ | ||
| Ziprasidone | Blocks dopamine D2 and serotonin 5HT2A receptors | -/+ | ||
| Risperidone | Blocks dopamine D2 and serotonin 5HT2A receptors | ++ | ||
| Aripiprazole | Partially agonizes dopamine D2, 5-HT1A receptors, blocks serotonin 5HT2A receptors | + | ||
| Paliperidone | Blocks dopamine D2 and serotonin 5HT2A receptors | + | ||
| Zotepine | Blocks dopamine D1, D2 and serotonin 5HT2A, 5HT2C, 5HT6 receptors | +++ | ||
| Sertindole | Blocks dopamine D2 and serotonin 5HT2A, 5HT2C alpha-1 adrenergic receptor | + | ||
| Amisulpride | Blocks dopamine D2 and D3 receptors | + | ||
| Antidepressants | ||||
| SSRIs | ||||
| Sertraline | Increase serotonin 5HT level by blocking reuptake at presynaptic terminals | ++ | ||
| Fluoxetine | ||||
| Excitalopram | ||||
| Trazodone | ||||
| Citalopram | ||||
| Paroxetine | ||||
| SNRIs | ||||
| Duloxetine | Block serotonin and norepinephrine reuptake in the synapse, increase postsynaptic receptors’ stimulation | ++ | ||
| Venlafaxine | ||||
| Levomilnacipran | ||||
| Atypical ADs | ||||
| Bupropion | Inhibits reuptake of dopamine and norepinephrine at the presynaptic cleft by binding to norepinephrine transporter and dopamine transporter | + | ||
| Mirtazapine | Increases release of norepinephrine into the synapse by blocking alpha-2 adrenergic receptors. Also antagonizes 5-HT receptor, increasing norepinephrine and dopamine | ++ | ||
| Viladozone | Enhances the release of serotonin across the brain’s serotonergic pathways specifically by inhibiting the serotonin transporter | |||
| Tricyclic ADs | ||||
| Imipramine | Increase norepinephrine and serotonin concentration by inhibiting reuptake at the presynaptic neuronal membrane | +++ | ||
| Nortriptyline | ||||
| Amitriptyline | ||||
| Doxepin | ||||
| MAOIs | ||||
| Phenelzine | Increase the levels of norepinephrine, epinephrine, serotonin, and dopamine by blocking reuptake of catecholamines and serotonin at the presynaptic neuronal membrane | ++ | ||
| Isocarboxazie | ||||
| Tranylcypromine |
- Citation: Khan MM, Khan ZA, Khan MA. Metabolic complications of psychotropic medications in psychiatric disorders: Emerging role of de novo lipogenesis and therapeutic consideration. World J Psychiatry 2024; 14(6): 767-783
- URL: https://www.wjgnet.com/2220-3206/full/v14/i6/767.htm
- DOI: https://dx.doi.org/10.5498/wjp.v14.i6.767